Efficacy and Safety of Nedaplatin or Cisplatin Combined with Paclitaxel in the Treatment of Advanced Lung Cancer and Esophageal Cancer:A Systematic Review / 中国药房

ABSTRACT

OBJECTIVE:To systematically review the efficacy and safety of nedaplatin or cisplatin combined with paclitaxel in the treatment of advanced non-small cell lung cancer(NSCLC)and esophageal cancer. METHOD:Retrieved from PubMed,CJFD and Wanfang Database,randomized controlled trials(RCT)about nedaplatin combined with paclitaxel(TN)or cisplatin combined with paclitaxel (TP) in the treatment of advanced NSCLC and esophageal cancer were collected. Meta-analysis was performed by using Rev Man 5.3 software after data extract and quality evaluation. RESULTS:Totally 7 RCTs were included,involving 505 pa-tients. Results of Meta-analysis showed,there were no significant differences in the short-term efficacy [NSCLCOR=1.08,95%CI (0.66,1.75),P=0.76;esophageal cancerOR=1.44,95%CI(0.68,3.06),P=0.34],1-year survival rate [NSCLCOR=1.21, 95%CI(0.60,2.44),P=0.59],2-year survival rate [NSCLCOR=1.01,95%CI(0.38,2.68),P=0.99],the incidence ofⅢ/Ⅳleuko-penia [esophageal cancerOR=1.36,95%CI(0.62,2.96),P=0.44],incidence ofⅢ/Ⅳthrombocytopenia [NSCLCOR=1.37,95%CI(0.64,2.92),P=0.42;esophageal cancerOR=0.97,95%CI(0.30,3.18),P=0.96] and incidence of Ⅲ/Ⅳ neutropenia [NSCLCOR=1.38,95%CI(0.70,2.74),P=0.35]. Compared with TP,TN can significantly reduce the incidences of nausea and vomiting [NSCLCOR=0.34,95%CI(0.20,0.60),P<0.001;esophageal cancerOR=0.16,95%CI(0.07,0.35),P<0.001] and nephrotox-icity [esophageal cancerOR=0.10,95%CI(0.02,0.55),P=0.009]. CONCLUSIONS:Both TN and TP show good efficacy in the treatment of NSCLC,but TN has lower incidences of astrointestinal reactions and nephrotoxicity.